drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Gene-modified cellular immunotherapy consisting of chimeric antigen receptor–engineered natural killer (NK) cells targeting mesothelin; administered by IV infusion every 2 weeks with dose escalation for advanced mesothelin-positive triple-negative breast cancer.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric antigen receptor–engineered natural killer (NK) cells targeting mesothelin; CAR binding to mesothelin on tumor cells triggers NK activation, leading to cytotoxic degranulation (perforin/granzyme) and cytokine release, causing lysis of mesothelin‑positive cancer cells.
drug_name
SZ011 CAR-NK
nct_id_drug_ref
NCT05686720